Carregando empresa
Just reported
Q3 2026 results
From Neuropace's results release of 12 de novembro de 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
US$ 23,1M
-16% y/y
+1,2% q/qGuided
—
No guide given
Operating income, adjusted
Actual
US$ 400K
Guided
—
No guide given
Company outlook
Full year 2026
- RevenueUS$ 91M – US$ 92M-8,5% y/y Lowered -9,0%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Neuropace is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$ 131,6BA+
SYKStryker Corp.US$ 117,9BA+
EWEdwards Lifesciences CorporationUS$ 61,6BA+
GEHCGE Healthcare Technologies Inc.US$ 37,5BA
GKOSGlaukos CorpUS$ 14,5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.28 de out. de 2026CAGraded C, now A
Demonstrações financeiras completas →
Construído a partir dos próprios documentos de Neuropace, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
